Semaglutide-based programs have helped patients lose an average of 15% of body weight in clinical trials — more than most diet programs produce in a lifetime. The catch: results require continued use, and not all programs are equal in what's actually included for the monthly price.
Find a Medical Weight Loss provider near youSemaglutide is a GLP-1 receptor agonist — a weekly injectable medication that mimics a gut hormone your body releases after eating. It suppresses appetite, slows digestion, and reduces food cravings at the neurological level. The result is a meaningful, sustained caloric deficit most patients can't achieve through willpower alone. It's the active ingredient in Wegovy (FDA-approved for weight loss) and Ozempic (FDA-approved for type 2 diabetes, widely used off-label for weight loss).
Med spa programs typically bundle the prescription, medication, injection supplies, and monitoring into a monthly program — a more accessible and often more affordable entry point than traditional weight loss clinics. Most programs use compounded semaglutide from an FDA-registered pharmacy, which runs significantly less than brand-name Wegovy. What's included in that bundle varies widely; always ask for a line-item breakdown. A full program should cover:
Treatment is a self-administered subcutaneous injection once per week, typically in the abdomen, thigh, or upper arm. Dosing starts low (0.25 mg/week) and titrates up over several weeks to manage side effects. Oral semaglutide options are also available for patients who prefer a daily pill over weekly injections.
Semaglutide programs are designed for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Good candidates have tried dietary changes and exercise without sustainable results, are committed to a monthly program, and understand the medication works best alongside lifestyle modifications — not as a standalone fix.
Semaglutide is not appropriate for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — there is an FDA black box warning for thyroid tumor risk. It should not be used during pregnancy or breastfeeding. Patients with a history of pancreatitis, severe GI disease, or diabetic retinopathy should consult with their physician before starting. Anyone scheduled for surgery requiring general anesthesia must disclose GLP-1 use to their surgical team — semaglutide's delayed gastric emptying increases aspiration risk under sedation.
GI side effects are the most common and expected part of treatment. Nausea, vomiting, constipation, and diarrhea affect the majority of patients — in the STEP clinical trials, 82.2% of semaglutide patients reported GI adverse events vs. 53.9% on placebo. Most are mild-to-moderate and peak during dose escalation in the first 8–12 weeks. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated all help.
More serious but rare risks include pancreatitis, gallbladder disease, and the thyroid tumor risk noted in the FDA black box warning. In clinical trials, medullary thyroid carcinoma was observed in animal studies; human risk is unclear but warrants the contraindication for anyone with a relevant personal or family history. Hypoglycemia (low blood sugar) is rare in people without diabetes but possible if combined with other blood-sugar-lowering medications.
Contact your provider if you experience severe abdominal pain that doesn't resolve (possible pancreatitis), persistent vomiting that prevents keeping food or fluids down, or yellowing of the skin or eyes (possible gallbladder issue). These require prompt medical evaluation, not a wait-and-see approach.
Browse med spas by city — Each city page includes med spas ranked by number of services, verified reviews, and featured status. Browse below to find top-rated providers near you.
The form has been successfully submitted.